ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals (Nasdaq:ORIC) announced inducement equity grants on December 1, 2025 to three newly hired non-executive employees who began in November 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ORIC Pharmaceuticals (Nasdaq:ORIC) announced inducement equity grants on December 1, 2025 to three newly hired non-executive employees who began in November 2025. The company granted 69,200 non-qualified stock options and 11,400 restricted stock units under the 2022 Inducement Equity Incentive Plan, subject to continued service through vesting dates.
The stock options use an exercise price equal to ORIC’s closing common stock price on the grant date. Options vest 25% after one year, then monthly at 1/36th of the remainder; RSUs vest one-third on each of the first three anniversaries. Grants were approved by the Compensation Committee per Nasdaq Rule 5635(c)(4) as material inducements to employment.
Details
News Market Reaction – ORIC
On Dec 8, the first trading day after this news, ORIC closed 4.36% below the previous close.
Data tracked by StockTitan Argus for the Dec 8 session.
Key Figures
- Stock options granted
- 69,200 options
- Non-qualified options granted on Dec 1, 2025 to three new employees
- RSUs granted
- 11,400 RSUs
- Restricted stock units granted on Dec 1, 2025 as inducement awards
- Initial option vesting
- 25% after 1 year
- Options cliff vesting on first anniversary of Grant Date
- RSU vesting schedule
- 1/3 annually over 3 years
- RSUs vest on each of the first three anniversaries of Grant Date
Historical Context
-
Phase 1b enozertinib data showed robust systemic and CNS activity.
-
Late-breaking oral ESMO Asia talks for enozertinib in EGFR-mutant NSCLC.
-
Planned ESMO Asia poster on enozertinib in HER2 exon 20 NSCLC.
-
Evercore Healthcare Conference fireside chat and investor meetings.
-
Q3 2025 financials, ORIC-944 updates, and cash runway into 2H 2028.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
non-qualified stock options financial
restricted stock units financial
Nasdaq Rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on December 1, 2025 (the “Grant Date”), ORIC granted a total of 69,200 non-qualified stock options and 11,400 restricted stock units to three new non-executive employees who began their employment with ORIC in November 2025.
These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each applicable vesting date. The stock options have an exercise price equal to the closing price of ORIC’s common stock on the Grant Date. Twenty-five percent (
The inducement grants were approved by ORIC’s Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4).
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib (ORIC-114), a brain penetrant inhibitor that selectively targets EGFR exon 20, EGFR atypical, and HER2 exon 20 mutations, being developed across multiple genetically defined cancers. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the vesting of the inducement grants; target indications for ORIC’s product candidates; the potential advantages of ORIC’s product candidates; and plans underlying ORIC’s clinical trials and development. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC’s product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license and collaboration agreements; the potential market for our product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 13, 2025, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.